177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.

Creative Commons License

Has Simsek D., Civan C., Ekenel M., Kuyumcu S., Sanli Y.

Clinical nuclear medicine, vol.46, no.5, pp.415-418, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 46 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1097/rlu.0000000000003563
  • Journal Name: Clinical nuclear medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.415-418
  • Keywords: Ga-68-PSMA, Lu-177-PSMA, mixed germ cell tumor, testis cancer, MEMBRANE ANTIGEN, EXPRESSION
  • Istanbul University Affiliated: Yes

Abstract

Prostate-specific membrane antigen (PSMA) overexpression in various tumors are demonstrated in both in vitro and in vivo studies. Prostate-specific membrane antigen-directed radionuclide therapies are generally used in prostate cancer and could be also useful in PSMA-avid other malignancies. Herein, we present a case of a 46-year-old male patient who had progressive metastatic testicular mixed germ cell tumor, despite repeated operations and treatments. Ga-68-PSMA PET/CT was performed to assess eligibility for Lu-177-PSMA therapy. Patient had intense PSMA uptake in metastatic lesions, and Lu-177-PSMA has been given to control of disease. However, alpha-fetoprotein level progressed, and mixed therapy response was detected in Ga-68-PSMA PET/CT.